False Statements and Perjury, and More from CRS
“Lying, or making a false statement, is a federal crime under a number of circumstances,” a newly updated report from the Congressional Research Service instructs.
“It is a federal crime to make a material false statement in a matter within the jurisdiction of a federal agency or department. Perjury is also a federal crime. Perjury is a false statement made under oath before a federal tribunal or official…. Subornation of perjury is inducing someone else to commit perjury. It, too, is a federal crime if the perjury induced is a federal crime. Finally, conspiracy to commit any these underlying crimes is also a separate federal crime.”
See False Statements and Perjury: An Overview of Federal Criminal Law, updated May 11, 2018.
Other new and updated reports from the Congressional Research Service include the following.
Iran Sanctions, updated May 11, 2018
Liberia: Political Transition and U.S. Relations, May 15, 2018
Permanent Legal Immigration to the United States: Policy Overview, updated May 11, 2018
Navy Lasers, Railgun, and Hypervelocity Projectile: Background and Issues for Congress, updated May 10, 2018
Is the U.S. Economy Growing Faster? Can It Grow Faster?, CRS Insight, May 8, 2018
NIH Funding: FY1994-FY2019, updated May 2, 2018
How FDA Approves Drugs and Regulates Their Safety and Effectiveness, updated May 8, 2018
Violence Against Journalists and Media workers in Mexico and U.S. Policy, CRS Memorandum, May 3, 2018
Compelling Presidential Compliance with a Judicial Subpoena, CRS Legal Sidebar, May 4, 2018
FAS commends the Senate Committee on Energy and Natural Resources for clearing a historic 75 pieces of legislation, including multiple crucial bills to confront the wildfire crisis.
The United States needs a strategic investment fund (SIF) to shepherd promising technologies in nationally vital sectors through the valley of death.
Standardizing support for Accessibility & Accommodations in federally funded research efforts would open opportunities for disabled scientists and their research programs.
The incoming administration must act to address bias in medical technology at the development, testing and regulation, and market-deployment and evaluation phases.